Voisin Laure, Julien Catherine, Duhamel Stéphanie, Gopalbhai Kailesh, Claveau Isabelle, Saba-El-Leil Marc K, Rodrigue-Gervais Ian Gaël, Gaboury Louis, Lamarre Daniel, Basik Mark, Meloche Sylvain
Institut de Recherche en Immunologie et Cancérologie, Montreal, Quebec, Canada.
BMC Cancer. 2008 Nov 17;8:337. doi: 10.1186/1471-2407-8-337.
The Ras-dependent ERK1/2 MAP kinase signaling pathway plays a central role in cell proliferation control and is frequently activated in human colorectal cancer. Small-molecule inhibitors of MEK1/MEK2 are therefore viewed as attractive drug candidates for the targeted therapy of this malignancy. However, the exact contribution of MEK1 and MEK2 to the pathogenesis of colorectal cancer remains to be established.
Wild type and constitutively active forms of MEK1 and MEK2 were ectopically expressed by retroviral gene transfer in the normal intestinal epithelial cell line IEC-6. We studied the impact of MEK1 and MEK2 activation on cellular morphology, cell proliferation, survival, migration, invasiveness, and tumorigenesis in mice. RNA interference was used to test the requirement for MEK1 and MEK2 function in maintaining the proliferation of human colorectal cancer cells.
We found that expression of activated MEK1 or MEK2 is sufficient to morphologically transform intestinal epithelial cells, dysregulate cell proliferation and induce the formation of high-grade adenocarcinomas after orthotopic transplantation in mice. A large proportion of these intestinal tumors metastasize to the liver and lung. Mechanistically, activation of MEK1 or MEK2 up-regulates the expression of matrix metalloproteinases, promotes invasiveness and protects cells from undergoing anoikis. Importantly, we show that silencing of MEK2 expression completely suppresses the proliferation of human colon carcinoma cell lines, whereas inactivation of MEK1 has a much weaker effect.
MEK1 and MEK2 isoforms have similar transforming properties and are able to induce the formation of metastatic intestinal tumors in mice. Our results suggest that MEK2 plays a more important role than MEK1 in sustaining the proliferation of human colorectal cancer cells.
依赖Ras的ERK1/2丝裂原活化蛋白激酶信号通路在细胞增殖控制中起核心作用,且在人类结直肠癌中经常被激活。因此,MEK1/MEK2的小分子抑制剂被视为针对这种恶性肿瘤进行靶向治疗的有吸引力的候选药物。然而,MEK1和MEK2在结直肠癌发病机制中的确切作用仍有待确定。
通过逆转录病毒基因转移在正常肠上皮细胞系IEC-6中异位表达MEK1和MEK2的野生型及组成型活性形式。我们研究了MEK1和MEK2激活对细胞形态、细胞增殖、存活、迁移、侵袭以及小鼠肿瘤发生的影响。使用RNA干扰来测试MEK1和MEK2功能在维持人类结直肠癌细胞增殖中的必要性。
我们发现,活化的MEK1或MEK2的表达足以使肠上皮细胞发生形态转化,失调细胞增殖,并在小鼠原位移植后诱导高级别腺癌的形成。这些肠肿瘤中有很大一部分转移至肝脏和肺。从机制上讲,MEK1或MEK2的激活会上调基质金属蛋白酶的表达,促进侵袭并保护细胞免于发生失巢凋亡。重要的是,我们表明沉默MEK2表达可完全抑制人类结肠癌细胞系的增殖,而MEK1失活的作用则弱得多。
MEK1和MEK2亚型具有相似的转化特性,并且能够在小鼠中诱导转移性肠肿瘤的形成。我们的结果表明,MEK2在维持人类结直肠癌细胞增殖方面比MEK1发挥更重要的作用。